The Powerful Neuroprotective Action of C1-Inhibitor on Brain Ischemia-Reperfusion Injury Does Not Require C1q

Maria Grazia De Simoni,* Emanuela Rossi,† Claudio Storini,* Simone Pizzimenti,* Cinara Echart,* and Luigi Bergamaschini†

From the Mario Negri Institute for Pharmacological Research,* Milan; and the Department of Internal Medicine,† University of Milan, Milan, Italy

C1-inhibitor (C1-INH) is a major regulator of the complement classical pathway. Besides this action, it may also inhibit other related inflammatory systems. We have studied the effect of C1-INH in C57BL/6 mice with focal transient brain ischemia induced by 30 minutes of occlusion of the middle cerebral artery. C1-INH induced a dose-dependent reduction of ischemic volume that, with the dose of 15 U/mouse, reached 10.8% of the volume of saline-treated mice. Four days after ischemia the treated mice had significantly lower general and focal neurological deficit scores. Fluoro-Jade staining, a marker for neuronal degeneration, showed that C1-INH-treated mice had a lower number of degenerating cells. Leukocyte infiltration, as assessed by CD45 immunostaining, was also markedly decreased. We then investigated the response to ischemia in C1q−/− mice. There was a slight, nonsignificant decrease in infarct volume in C1q−/− mice (reduction to 72.3%) compared to wild types. Administration of C1-INH to these mice was still able to reduce the ischemic volume to 31.4%. The study shows that C1-INH has a strong neuroprotective effect on brain ischemia/reperfusion injury and that its action is independent from C1q-mediated activation of classical pathway. (Am J Pathol 2004, 164:1857–1863)
Materials and Methods

Animals

Male C57BL/6 mice (26 to 28 g; Charles River, Calco, Italy) and mice carrying a targeted deletion of the gene encoding C1q (C57BL/6.C1qa−/−, classical pathway deficiency).27,30 These mice have no overt phenotype with no evidence of autoimmunity. On intraperitoneal exposure to prions they show partial or full protection against spongiform encephalopathy.31,32

Surgery

Transient focal cerebral ischemia was achieved by middle cerebral artery occlusion as previously described.19 Anesthesia was induced by 5% isoflurane in N2O/O2 (70/30%) mixture and maintained by 1.5 to 2% isoflurane in the same mixture. To confirm the adequacy of the vascular occlusion in each animal, blood flow was measured by laser Doppler flowmetry (Transonic BLF-21) using a flexible 0.5-mm fiberoptic probe (type M, 0.5 mm diameter; Transonic) positioned on the brain surface and secured with impression material on the skull at the following coordinates: AP = −1 mm; L = −3.5 mm.33 Briefly, the left common carotid artery was exposed and the external carotid artery and its branches, including the occipital artery and the superior thyroid artery were isolated and cauterized. The pterygopalatine artery was ligated and the external carotid artery cauterized. A 5-0 monofilament nylon suture, blunted at the tip by heat and coated in poly-L-lysine, was introduced into the internal carotid artery through the external carotid artery stump and advanced to the anterior cerebral artery stump and advanced to the anterior cerebral artery so as to block its bifurcation into the anterior cerebral artery and the middle cerebral artery. The filament was advanced until a >70% reduction of blood flow, compared to preischemic baseline, was observed. At the end of the 30-minute ischemic period, blood flow was restored by carefully removing the nylon filament.

Drug Treatment

Mice received an intravenous injection of C1-INH (C1 esterase inhibitor, 1 U corresponding to the activity of 1 ml of normal plasma; Baxter-Immuno, Pisa, Italy) or the same volume (150 μl) of saline at different doses and at different times from ischemia.

Quantification of Infarct Size and Volume

Mice were deeply anesthetized with Equitensin (120 μl/mice i.p.) and brains were rapidly frozen by immersion in isopentane at −45°C for 3 minutes before being sealed into vials and stored at −70°C until use. For lesion size determination, 40-μm coronal brain sections were cut serially at 320-μm intervals and stained with neutral red (Neutral Red Gurr Certistain; BDH, UK).19 On each slice, infarcted areas were assessed blindly and delineated by the relative paleness of histological staining. The infarcted area was determined by subtracting the area of the healthy tissue in the ipsilateral hemisphere from the area of the contralateral hemisphere on each section. Infarct volumes were calculated by the integration of infarcted areas on each brain slice as quantified with computer-assisted image analyzer and calculated by the Analytical Image System (Imaging Research Inc., Brock University, St. Catharines, Ontario, Canada).

Neurological Deficits

Four days after ischemia, each mouse was rated on two neurological function scales unique to the mouse.19,34 For both scales mice were scored from 0 (healthy mouse) to 28. The score given represents the sum of the results of all categories for each scale. General deficit scale evaluates the hair, ears, eyes, posture, spontaneous activity, and epileptic behavior. Focal deficit scale evaluates the body symmetry, gait, climbing on a surface held at 45°, circling behavior, front limb symmetry, compulsory circling, whisker response to a light touch. All of the experiments were run by a trained investigator blinded to the experimental conditions. Data were expressed as median and 25th to 75th percentiles because intervals between scores are not equal.

Brain Transcardial Perfusion

Mice were deeply anesthetized with Equitensin (120 μl/mouse i.p.) and transcardially perfused with 20 ml of phosphate-buffered saline (PBS) 0.1 mol/L, pH 7.4, followed by 50 ml of chilled paraformaldehyde (4%) in PBS. After carefully removing the brains from the skull, they were transferred to 30% sucrose in PBS at 4°C overnight for cryoprotection. The brains were then rapidly frozen by immersion in isopentane at −45°C for 3 minutes before being sealed into vials and stored at −70°C until use.

Fluoro-Jade Labeling

Fluoro-Jade labeling was performed on perfused brains.35 Briefly, 20-μm mounted sections were dried
and rehydrated in ethanol (100 to 75%) and distilled water, then they were incubated in 0.06% potassium permanganate, washed in distilled water, and transferred to 0.001% Fluoro-Jade staining solution. After staining, the sections were rinsed in distilled water, dried, immersed in xylene, and coverslipped.

**Immunocytochemistry**

Forty-µm-thick coronal sections, prepared from perfused brains as described above, were used for assessment of leukocyte immunostaining. Briefly, free-floating sections were rinsed for 30 minutes in 0.4% Triton X-100 in PBS, 0.1 mol/L, pH 7.4, followed by 15 minutes in 0.1% Triton X-100 and 3% fetal calf serum in PBS. The primary antibody was diluted in 0.1% Triton X-100 in PBS containing 3% fetal calf serum and slices were incubated at 4°C overnight with the biotinylated primary monoclonal antibody (rat anti-mouse CD45, 1:1500; BD Biosciences Pharmingen, San Diego, CA). After three 5-minute washes in PBS, immunoreactivity was tested by the avidin-biotin-peroxidase technique (Vectastain ABC kit; Vector Laboratories, Burlingame, CA). The sections were then reacted by incubation with 3′3-diaminobenzidine (Sigma, Munich, Germany) in Tris-HCl-buffered saline, pH 7.4, and 0.01% H2O2, and the signal amplified using nickel ammonium. After 3′-3-diaminobenzidine incubation, three 5-minute washes were done with Tris-HCl-buffered saline, then the slices were mounted onto gelatin-coated slides, dried, dehydrated through graded alcohol, fixed in xylene, and coverslipped using DPX mountant (BDH, Poole, UK) before light microscopy analysis.

**Results**

C1-INH-treated C57BL/6 mice had a dose-dependent reduction of ischemic volume that reached 10.8% of the volume of saline-treated mice (60.01 ± 9.32 mm³ and 6.5 ± 2.81 mm³, saline and C1-INH-treated mice, respectively) with the dose of 15 U/mouse (Figure 1). Also

5 U/mouse was able to significantly reduce the ischemic lesion (26.28 ± 4.61 mm³, reduction to 43.8%), whereas 1 U/mouse was ineffective (Figure 1). In all these experiments the inhibitor was given at the beginning of the ischemic period (pre). When given at reperfusion, ie, 30 minutes after the beginning of ischemia, C1-INH was still able to significantly reduce the ischemic volume (27.12 ± 6.22 mm³, reduction to 45.2%, Figure 1), but its efficacy was completely lost when the inhibitor was given after 30 minutes of reperfusion (ie, 60 minutes after the beginning of ischemia).

To evaluate if the marked reduction of the ischemic lesion observed 24 hours after ischemia resulted in a reduced functional impairment, neurological deficits were evaluated daily, starting from day 1 for 4 days, in mice receiving saline or 15 U/mouse of C1-INH at the beginning of ischemia (black dots, n = 8) or with saline (white dots, n = 9). Data are expressed as median and 25th to 75th percentiles. Differences between curves were evaluated by two-way analysis of variance for repeated measures. Differences between scores at a given time were evaluated by Fisher’s exact test. **, P < 0.01.

In the same mice we then analyzed the effect of ischemia and C1-INH treatment on neurodegeneration to assess if neurons were actually spared by the inhibitor treatment. The staining with Fluoro-Jade, a marker for neuronal degeneration, was evaluated 4 days after ischemia. In saline-treated mice, positive cells were consistently observed in temporal cortex where they
appeared as extended clusters of fluorescent cells (four of four) often amid necrotic tissue (Figure 3A). Few and sparse positive cells could also be detected in hippocampus [dentate gyrus hilus, three mice (Figure 3C) and CA1 pyramidal cells, one mouse], striatum (two mice), and thalamus (two mice). In mice treated with C1-INH the number of degenerating cells was greatly reduced and the general structure of the brain tissue, well preserved compared to saline-treated mice. Three mice of four showed small groups of Fluoro-Jade-positive cells in temporal cortex (Figure 3B). Positive cells could not be found in the other brain regions in these mice.

Leukocyte infiltration was then evaluated by CD45 immunostaining. Twenty-four hours after ischemia, infiltrating leukocytes were clearly detectable in hypothalamus (Figure 4A) and few, sparse cells were present in cortex, hippocampus and striatum (not shown). C1-INH administration (15 U/mouse, pre) strongly reduced leukocyte infiltration and only few cells could be observed in the hypothalamic area (Figure 4B).

Because C1-INH, besides being a potent inhibitor of the complement classical pathway, may also act on lectin and alternative pathways and on other related inflammatory systems, we set to investigate the response to ischemia in C1q−/− mice. There was a slight, nonsignificant decrease in infarct volume in C1q−/− mice (43.42 ± 6.73 mm³, reduction to 72.3%) compared to wild types (C57BL/6, see above). Administration of C1-INH (15 U/mouse, pre) to C1q−/− mice was still able to exert its neuroprotective effects as shown by the significant reduction of the ischemic volume to 33% (18.2 ± 5.05 mm³) (Figure 5).

**Discussion**

This study shows the powerful neuroprotective action of C1-INH and establishes that this action does not require the presence of C1q. C1-INH dose dependently reduced the ischemic volume. The highest dose used, 15 U/mouse, was able to reduce the ischemic volume to 10.8%, a remarkably high degree of protection, and 5 U/mouse reduced it to 43.8%, still a highly significant effect. Data obtained measuring C1-INH activity in mouse plasma showed that the inhibitor is cleared within 1 hour (data not shown), whereas in humans the C1-INH half-life is ~35 hours, indicating that C1-INH doses used in this study cannot be directly compared to those used in humans. Notably the minimal effective dose (5 U) is only 1.8 times the safe loading dose used in humans. The present finding confirms and extends our previous data and all together show the marked protective action of this inhibitor that is effective on both inbred and outbred...
mouse strains. Its efficacy in brain ischemia-reperfusion injury has recently been described also in rats. Administration of C1-INH at the beginning of ischemia or at the beginning of reperfusion markedly reduced the ischemic volume, whereas the effect was lost when it was administered after 30 minutes of reperfusion. The early and narrow time window of the protection shows the critical role of the systems inhibited by C1-INH in the very first phase of reperfusion of the ischemic brain. We have previously shown a marked C1-INH immunostaining in the brain capillary endothelium and in the tissue around them, indicating that the inhibitor can reach the brain compartment where it could possibly act. However our data do not allow to draw conclusions on which is the compartment relevant to C1-INH neuroprotection, plasma, brain tissue, or both.

The use of Fluoro-Jade staining to evidence degenerating neuronal cells, allowed us to investigate whether C1-INH action resulted in sparing of these cells. Preliminary experiments showed that 24 hours after ischemia, Fluoro-Jade-positive cells were less in C1-INH-treated mice compared to mice receiving saline (data not shown). To assess if this effect was because of a delay in degenerating processes or to a real neuroprotection induced by the treatment, we then analyzed Fluoro-Jade-positive cells 4 days after ischemia and fully confirmed the observation that neurodegeneration was actually inhibited by C1-INH treatment.

We then investigated whether C1-INH, being a major inhibitor of inflammatory systems, could affect given aspects of the inflammatory response. C1-INH induced a marked reduction of leukocyte infiltration in the brain tissue. As documented in experimental animal models as well as in patients, after ischemia leukocytes accumulate in brain parenchyma as a consequence of a cascade of events including margination, adhesion, and transmigration through the vessel wall. This represents an important aspect of the inflammatory response triggered by the ischemic event. These cells contribute to the evolution of tissue injury by several possible mechanisms including microvascular obstruction by neutrophils and production of cytokines and other toxic mediators. An additional important aspect when assessing the protective effect of a compound on ischemia-reperfusion injury is the evaluation of functional deficits. C1-INH induces a progressive recovery in both general and focal neurological deficits indicating an amelioration of the appearance of the mice, their motor performance, their reactivity, and response to stimuli. All these data show that C1-INH is a powerful neuroprotective agent.

The experiments performed using C1q−/− mice show only a slight decrease in ischemic volume compared to wild types, indicating that ischemia-reperfusion brain injury is not dependent on C1q. Interestingly, recent data on gastrointestinal ischemia-reperfusion injury report a similar observation. In view of the several substrates on which C1-INH may act (see Introduction), the finding that this inhibitor is still able to markedly reduce the reperfusion injury in C1q−/− mice, opens the question of which is the action that results in neuroprotection. Recent data from studies in different organs now support the view that inhibition of classical, lectin, or alternative complement pathway, is beneficial to reduce ischemia reperfusion injury. Furthermore, the presence of tissue kallikrein in the brain tissue and the identification of bradykinin B2 receptors on brain cells are in line with a role also for this system in nervous system pathophysiology. Specifically, the involvement of the contact-kinin system in ischemia-reperfusion injury is supported by data showing the effectiveness of bradykinin B2 receptor antagonists in reducing ischemic brain damage.

Figure 4. Leukocyte infiltrating the hypothalamic area in ischemic mice treated with saline (A) or C1-INH (B) as in Figure 2, 24 hours after ischemia. Scale bar, 100 μm. Insets show CD45-positive cells at higher magnification.

Figure 5. Infarct volume assessed 24 hours after ischemia in C1q−/− mice receiving saline (SAL) or 15 U of C1-INH at the beginning of ischemia. For comparison the ischemic volume of wild types (C57BL/6 mice) is also reported (black column, see Figure 1). Data are expressed as mean ± SEM (n = 7 to 10 mice per group). **, P < 0.01 versus wild types (black column); *, P < 0.05 versus C1q−/− (gray column), Tukey-Kramer test.
cumulating evidence suggests that these pathways may be not as independent as originally thought, and their complex cross-talk and interplay has not allowed dissection of each other specific role yet.4

In conclusion the present study shows that: 1) C1-INH has a strong neuroprotective effect; 2) it acts on a system that is crucial in the early phases of the ischemic injury development; 3) its action is independent from C1q-mediated activation of classical pathway; 4) other complement pathways or inflammatory systems, possibly the contact-kinin system, may be involved in ischemia-reperfusion injury. Blockade of such systems can reduce the numerous inflammatory reactions that in turn condition the postischemic brain function.

References


